HOME >> MEDICINE >> NEWS
US FDA grants full approval to DOXIL(R) following submission of phase III data

Bridgewater, N.J. February 7, 2005 -- The U.S. Food and Drug Administration (FDA) has granted full approval to DOXIL (doxorubicin HCl liposome injection) for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. DOXIL, marketed in the United States by Tibotec Therapeutics, Division of Ortho Biotech Products, L.P., originally received accelerated approval for refractory ovarian cancer in June 1999. As a result of the full approval, the product label for DOXIL has been updated to include survival, time to disease progression and tumor response rate data from a randomized Phase III clinical study.

Under accelerated approval, DOXIL was indicated for the treatment of metastatic ovarian cancer in patients with disease that was refractory to both paclitaxel- and platinum-based chemotherapy regimens. This approval was based on tumor response rates from three Phase II studies. According to the terms of the accelerated approval, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) completed a randomized Phase III clinical study to formally demonstrate the drug's clinical benefit in patients with relapsed ovarian cancer. In March 2004, J&JPRD submitted a supplemental new drug application (sNDA) based on data from the Phase III study.

"The Phase III data provide evidence of the product's clinical benefit for patients with relapsed ovarian cancer," commented Alan N. Gordon, M.D., of the University of Arizona School of Medicine and Arizona Gynecologic Oncology, in Phoenix, Ariz., and lead author of the Phase III study, known as DOXIL Study 30-49.

In the randomized, multi-center, open-label, Phase III study, 474 patients with recurrent epithelial ovarian cancer were randomly assigned to receive either DOXIL 50 mg/m2 every 28 days or topotecan HCl 1.5 mg/m2/day for five consecutive days every 21 days. A total of 239 patients received DOXIL; 235 patients received
'"/>


7-Feb-2005


Page: 1 2 3

Related medicine news :

1. UNH launches 2nd spinout company with NIH grants
2. Disease testing for immigrants: Discrimination disguised as public health policy
3. Four teams awarded inaugural translational cancer research grants
4. Immigrants, beware: Living in the United States is fattening
5. Prevalence of obesity among immigrants increases with longer residency in US
6. FDA grants accelerated approval of TYSABRI, formerly antegren, for the treatment of MS
7. Dana-Farber receives CDC grants to develop health promotion/prevention programs in the work place
8. Speech recognition experts at OGI School of Science & Engineering receive nearly $700,000 in grants
9. Should compulsory screening of immigrants be part of UK public health policy?
10. NIH grants support health disparities biomedical research
11. NCCAM awards planning grants for International Centers for Research

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA grants full approval DOXIL following submission phase III data

(Date:5/27/2015)... Cincinnati Veterans Affairs Medical Center invites caregivers ... from noon-2p.m. in the auditorium. This event provides ... full-time assistance to Veterans in their homes. ... conducted by the medical center staff. In order ... home, the caregiver must provide monthly care including room ...
(Date:5/27/2015)... Thermage was the first to come out with a ... coinciding with the release of NXT or CPT, the second-generation ... was the first practice in New York to debut the ... that had never been achieved before non-surgically. Even today, ... by many as the leading skin tightening device. The ...
(Date:5/27/2015)... May 27, 2015 StatRad, a leading ... is pleased to introduce Mr. Chris E. Hafey as ... a proven track record of leading new development projects ... domain. He most recently served as the Chief Technology ... role of Chief Architect for Vital Images. , "I ...
(Date:5/27/2015)... Western University of Health Sciences’ 34th Annual Commencement ... and one profound last. , The May 20-22, 2015 ... time the university surpassed more than 1,000 graduates at ... Biomedical Sciences (GCBS) alumnus graduated from the College of ... fifth and final ceremony of its three-day Commencement – ...
(Date:5/27/2015)... Ticket Down is a reputable source for 2015 ... super hot during the 2014-15 NBA season and they delighted their ... final score of 118-88. , For the Cavaliers, this ... when they lost to the San Antonio Spurs. Once Lebron ... Cavaliers making it to the NBA finals increased tenfold. The ...
Breaking Medicine News(10 mins):Health News:Non-Surgical Fat Reduction and Skin Tightening Procedures, Thermage and Exilis, Increase 200% at Precision Aesthetics in New York, April 2015 2Health News:StatRad Introduces Mr. Chris E. Hafey as Chief Technology Officer, and the Release of its Advanced Pure HTML5 DICOM Image Uploader 2Health News:WesternU Commencement Celebrates Achievements of Graduates and Founding President 2Health News:WesternU Commencement Celebrates Achievements of Graduates and Founding President 3Health News:WesternU Commencement Celebrates Achievements of Graduates and Founding President 4Health News:WesternU Commencement Celebrates Achievements of Graduates and Founding President 5Health News:Cavs NBA Finals Tickets: Ticket Down Slashes Ticket Prices on Cleveland Cavaliers 2015 NBA Finals Tickets at Quicken Loans Arena and Offers Valuable Promo Code 2
(Date:5/27/2015)... 27, 2015 Research ... addition of the  "North America Mammography Market ... 2019)"  report to their offering. ... is a detailed type of imaging that ... breasts. A mammography exam, called a mammogram, ...
(Date:5/27/2015)... May 27, 2015 OpportunityAnalyzer: Sepsis - Opportunity ... patients suffer from a series of diverse complications arising ... the blood or tissues, which cause a rapidly progressing ... mortality rates near 50% depending on disease severity. The ... systems of the global marketplace, which for the purposes ...
(Date:5/27/2015)... YORK , May 27, 2015 PharmaPoint: ... Forecast and Market Analysis to 2022 - Event-Driven Update ... dominated by generics and GlaxoSmithKline,s Benlysta is the only ... more than 50 years. Following Benlysta,s launch, patients, uptake ... price-tag Benlysta has managed to grow the lupus market ...
Breaking Medicine Technology:North America Mammography Market - Growth, Trends And Forecasts (2014 - 2019) 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update 2PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update 3
Cached News: